Sustained response of primary cutaneous CD30 positive anaplastic large cell lymphoma to bexarotene and photopheresis

Leukemia and Lymphoma

Volumn 50, Issue 8, 2009, Pages 1389-1391

  Sheehy, Oonagh ^a   Catherwood, Mark ^a   Pettengell, Ruth ^b   Morris, T C Curly ^a  

^a BELFAST CITY HOSPITAL   (United Kingdom)

^b ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEXAROTENE; CD30 ANTIGEN; OMEGA 3 FATTY ACID; STATIN; CHOP PROTOCOL; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; TETRALIN DERIVATIVE; VINCRISTINE;

ABDOMINAL WALL; ADULT; BONE MARROW; BREAST LESION; CANCER RELAPSE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FACE INJURY; FEMALE; HUMAN; LARGE CELL LYMPHOMA; LETTER; MULTIPLE CYCLE TREATMENT; NECK INJURY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PUVA; SALVAGE THERAPY; T LYMPHOCYTE RECEPTOR GENE; THIGH; FACE TUMOR; MULTIMODALITY CANCER THERAPY; PATHOLOGY; SKIN TUMOR; TUMOR RECURRENCE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; FACIAL NEOPLASMS; FEMALE; HUMANS; LYMPHOMA, PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL; NEOPLASM RECURRENCE, LOCAL; PHOTOPHERESIS; PREDNISONE; SALVAGE THERAPY; SKIN NEOPLASMS; TETRAHYDRONAPHTHALENES; VINCRISTINE;

EID: 77649325792     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190903045385     Document Type: Letter

References (9)

1. Willemze R, Jaffe ES, Burg G, et al. WHO - EORTC classification for cutaneous lymphomas. Blood 2005;105:3768-3785. (Pubitemid 40656118)
2. Bekkenk MW, Geelen FA, van Voorst Vader PC, et al. Primary and secondary cutaneous CD30 (+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 2000;95:3653-3661. (Pubitemid 30412833)
3. Liu HL, Hoppe RT, Kohler S, et al. CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. J Am Acad Dermatol 2003;49:1049-1058. (Pubitemid 37475476)
4. Zhang C, Hazarika P, Ni X, et al. Induction of apoptosis by bexarotene in cutaneous T cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res 2002;8:1234-1240. (Pubitemid 34517663)
5. Edelson RL, Berger CL, Gasparro FP. Treatment of cutaneous T-cell lymphoma by extra corporeal photochemotherapy. N Eng J Med 1987;316:297-303.
6. Talpur R, Ward S, Aspisarnthanarax N, et al. Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 2002;47:672-684. (Pubitemid 35239327)
7. Coors EA, von den driesch P. Treatment of mycosis fungoides with bexarotene and psoralen plus ultraviolet A. Br J Dermatol 2005;152:1379-1381. (Pubitemid 40933460)
8. McGinnis KS, Ubriani R, Newton S, et al. The addition of interferon g to oral bexarotene therapy with photopheresis for sezary syndrome. Arch Dermatol 2005;141:1176-1178. (Pubitemid 41373981)
9. McGinnis KS, Shapiro M, Vittorio CC, et al. Psoralen plus long wave UV-A (puva) and bexarotene therapy. Arch Dermatol 2003:139:771-775.